Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BCL3 | P20749 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071298 | 0.82 | HDAC1 (0.47) | KMT2APOLBMEN1KDM4EALDH1A1 | |
| SCHEMBL6071238 | 0.82 | PARP1 (0.55) | SMYD2KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL6071474 | 0.82 | SMYD2 (0.52) | SMYD2KMT2AMEN1RAD52SMN1; SMN2 | |
| SCHEMBL6071459 | 0.80 | RAD52 (0.44) | KMT2APOLBMEN1RAD52KDM4E | |
| SCHEMBL6070823 | 0.77 | HDAC3 (0.42) | SMN1; SMN2 | |
| SCHEMBL6071204 | 0.77 | SHMT2 (0.54) | SMYD2POLBKDM5BSMN1; SMN2KDM4E | |
| SCHEMBL6071049 | 0.76 | HDAC3 (0.38) | KMT2AMEN1 | |
| SCHEMBL6070184 | 0.75 | NPC1 (0.38) | KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL6071024 | 0.75 | HPGD (0.50) | KMT2APOLBMEN1SMN1; SMN2KDM4E | |
| SCHEMBL6071016 | 0.74 | MAPK1 (0.44) | POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | claimed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | SMYD2 4154/4885KMT2A 2104/4885POLB 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.